Acute coronary syndromes as auto-inflammatory disorders

Current Pharmaceutical Design

Volumn 18, Issue 28, 2012, Pages 4370-4384

  Suzuki, Makoto ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute coronary syndromes; Cholesterol; Inflammation; Leukocyte; Platelet; Reactive oxygen species; Vascular endothelial cell; Vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CD16 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THROMBIN; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; AUTOINFLAMMATORY DISEASE; BLOOD CLOT LYSIS; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INTRAVASCULAR ULTRASOUND; LEUKOCYTE ACTIVATION; MONOCYTE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOCYTE; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ACUTE CORONARY SYNDROME; ANIMALS; BLOOD PLATELETS; CHOLESTEROL; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LEUKOCYTES; MUSCLE, SMOOTH, VASCULAR; REACTIVE OXYGEN SPECIES;

EID: 84866419026     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802481228     Document Type: Review

References (152)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Maseri A, Liuzzo G, Biasucci LM. Pathogenic mechanisms in unstable angina. Heart 1999; 82: Suppl 1: 12-14
3. Lindahal B, Toss H, Siegbahan A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139-1147.
4. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 2003; 108: 2317-2322.
5. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interlukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993; 126: 1299-1304.
6. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of inhospital coronary events. Circulation 1999; 99: 2079-2084.
7. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interlukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
8. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
9. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49-57.
10. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
11. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
12. Hamm CW, Nef HM, Rolf A, Möllmann H. Calcium and Creactive protein. Hot enough to predict the future? J Am Coll Cardiol 2011; 57: 1465-1467.
13. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
15. van der Wal A, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
16. Fernandez-Ortiz A, Badimon JJ, Falke E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque component: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
17. Stone GW, Maehara A, Lansky AJ, et al. for the PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235.
18. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJG, Becker AE, et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998; 32: 655-662.
19. Suzuki M, Inaba S, Nagai T, Tatsuno H, Kazatani Y. Relation of Creactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction. Am J Cardiol 2003; 91: 331-333.
20. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177.
21. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325.
22. Wartman WB. Occlusion of the coronary arteries by hemorrhage into their walls. Am Heart J 1938; 15: 459-470.
23. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922.
24. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-808.
25. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001; 37: 1284-1288.
26. Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo. A new method of detection by application of a special thermography catheter. Circulation 1999; 99: 1965-1971.
27. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque. A multifocal disease. Circulation 2003; 107; 2072-2075.
28. Mauriello A, Sangiorgi G, Fratoni S, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopatholgic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1585-1593.
29. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000; 35: 956-962.
30. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
31. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594-1599.
32. Serneri GGN, Boddi M, Modesti PA, et al. Immunomediated and ischemia-independent inflammation of coronary microvessels in unstable angina. Circ Res 2003; 92: 1359-1366.
33. Serneri GGN, Boddi M, Modesti PA, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 2004; 94: 1630-1637.
34. Haller H, Lindschau C, Erdmann B, Quass P, Luft FC. Effects of intracellular angiotensin II in vascular smooth muscle cells. Circ Res 1996; 79: 765-772.
35. Luft FC. Cardiac angiotensin is upregulated in the hearts of unstable angina patients. Circ Res 2004; 94: 1530-1532.
36. Ridkar PM, Rifai N, Pfeffer MA, et al. for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-844.
37. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction. Considerations for the bench and perspectives for the clinic. Circ Res 2011; 108: 593-606.
38. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008; 451: 953-957.
39. Verheye S, De Meyer GRY, Langenhove GV, Knaapen MWM, Kockx MM. In vivo temperature heterogeneity of atherosclerotic plaques is determined by plaque composition. Circulation 2002; 105: 1596-1601.
40. Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006; 47: 2405-2412.
41. Kawaguchi R, Oshima S, Mingu M, et al. Usefulness of virtual histology intravascular ultrasound to predict distal embolization for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2007; 50: 1641-1646.
42. Jaffer FA, Vinegoni C, John MC, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008; 118: 1802-1809.
43. Razansky RN, Rosenthal A, Mallas G, Razansky D, Jaffer FA, Ntziachristos V. Near-infrared fluorescence catheter system for two-dimensional intravascular imaging in vivo. Opt Express 2010; 18: 11372-11381.
44. Tawakol A, Migrino RQ, Hoffman U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005; 12: 294-301.
45. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-1824.
46. Flogel U, Ding Z, Hardung H, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008; 118: 140-148.
47. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PETCT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117: 379-387.
48. Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation 2003; 108: 282-285.
49. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996; 84: 331-334.
50. Suzuki M, Saito M, Nagai T, Saeki H, Kazatni Y. Systemic versus coronary levels of inflammation in acute coronary syndromes. Angiology 2006; 57: 459-463.
51. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest.2003; 111: 1805-1812.
52. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 350: 1450-1452.
53. Wang C-H, Li S-H, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790.
54. Tomai F, Crea F, Gaspardone A, et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2001; 104: 1471-1476.
55. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting Creactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221.
56. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-2888.
57. MacNeill BD, Jang IK, Bouma BE, et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol 2004; 44: 972-979.
58. Heistad DD. Unstable coronary-artery plaques, N Engl J Med 2003; 349: 2285-2287.
59. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
60. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002; 106: 3024-3030.
61. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
62. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
63. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survial and Ventricular Enlargement trial: SAVE Investigators. Circulation 1994; 90: 1731-1738.
64. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
65. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
66. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378.
67. Hoshida S, Kato J, Nishino M, et al. Increased angiotensinconverting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001; 103: 630-633.
68. Murphy TJ, Alexander RW, Grienberg KK, Runge MA, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-236.
69. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
70. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007; 27: 943-948.
71. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor of oxidized lowdensity lipoprotein. Circulation 1999; 100: 899-902.
72. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factorkappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-8.
73. Pastore L, Tessitore A, Martinott S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increase soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-1652.
74. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-651.
75. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
76. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 2000; 212: 155-169.
77. Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-541.
78. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-183.
79. Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implication for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
80. Schöbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1093.
81. Buhlmann JE, Noelle RJ. Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol 1996; 16: 83-89.
82. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
83. Chen Y, Chen J, Xiong Y, et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 2006; 345: 106-117.
84. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
85. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649-655.
86. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002; 319: 19-26.
87. Wang Y, Li L, Tan HW, et al. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clin Cardiol 2007; 30: 86-91.
88. Heeschen C, Dimmeler S, Hamm CW, et al. for the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
89. Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
90. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: A Thrombolysis In Myocardial Infarction 10 substudy. Circulation 2000; 102: 2329-2334.
91. Ardission D, Merlini PA, Ariens R, Coppola R, Bramucchi E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-771.
92. Toschi V, Gallo R, Lettiono M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
93. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
94. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucchi PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-771.
95. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
96. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-325.
97. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-735.
98. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
99. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-264.
100. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-2894.
101. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
102. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561-564.
103. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear kappaB (NF-kappaB) and tumor necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br Haematol 2000; 110: 130-134.
104. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
105. Kaneider NC, Forster E, Mosheimer B, Stum DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxininduced endothelial adherence of neutrophils by antithombin. Thromb Haemost 2003; 90: 1150-1157.
106. Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
107. Semenza GL. Life with oxygen. Science 2007; 318: 62-64.
108. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
109. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-23763.
110. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 2005; 201: 105-115.
111. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000; 342: 626-633.
112. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103: 18154-18159.
113. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586: 4055-4059.
114. Reynolds HR, Hochman JS. Cardiogenic chock: current concepts and improving outcomes. Circulation 2008; 117: 686-697.
115. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
116. Sagan L. On the origin of mitosing cells. J Theor Biol 1967; 14: 255-274.
117. Deitch EA, Xu D, Kaise VL. Role of the gut in the development of injury-and shock induced SIRS and MODS: the gut-lymph hypothesis, a review. Front Biosci 2006; 11: 520-528.
118. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-107.
119. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
120. Kloner RA, Rude RE, Carlson N, Marko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62: 945-952.
121. Kloner RA, Ganote CE, Jenning RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-1508.
122. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97: 795-804.
123. Suzuki M, Sakaue T, Tanaka M, et al. Association between right bundle branch block and impaired myocardial tissue-level reperfusion in patients with acute myocardial infarction J Am Coll Cardiol 2006; 47: 2122-2124.
124. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial No-Reflow in Humans. J Am Coll Cardiol 2009; 54; 281-292.
125. Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca2+ modulation during postischemic reperfusion in rat heart. Am J Physiol 1995; 268: H100-H111.
126. Boll R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygenderived free radicals contribute to postischmic myocardial dysfunction in the intact dog. Proc Natl Acad Sci USA 1989; 86: 4695-4699.
127. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999; 49: 91-102.
128. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 2004; 61: 372-385.
129. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006; 101: 359-372.
130. Suzuki M, Shimizu H, Miyoshi A, Takagi Y, Sato S, Nakamura Y. Association of coronary inflammation and angiotensin II with impaired microvascular reperfusion in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2011; 146: 254-256.
131. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-1204.
132. Granger CB, Mahaffey KW, Weaver WD, et al. for the COMMA investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190.
133. Armstrong PW, Granger CB, Adams PX, et al. The APEX AMI investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43-51.
134. Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994; 89: 1982-1991.
135. Guan W, Osanai T, Kamada T, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 2003; 41: 699-705.
136. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006; 70: 832-837.
137. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1928-1934.
138. Ly HQ, Denault A, Dupuis J, et al. A pilot study: the noninvasive surface cooling thermoregulatory system for mild hypothermia induction in acute myocardial infarction (The NICAMI Study). Am Heart J 2005; 150: 933.e9-933.e13.
139. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-481.
140. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 2003; 285: H579-H588.
141. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-2148.
142. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 2005; 65: 361-367.
143. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-460.
144. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003; 60: 617-625.
145. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
146. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: Protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010; 121: 2437-2445.
147. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
148. Draude G, von Hundelshausen P, Frankenberger M, Ziegler-Heitbrock HW, Weber C. Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. Am J Physiol 1999; 276: H1144-H1149.
149. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
150. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
151. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
152. Tsujioka H, Imanishi T, Ikegima H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54: 130-138.